We are live on ! Find out more
IGMS

IGM Biosciences
IGMS

Delisted

IGMS was delisted on the 13th of August, 2025.

Back to rankings

87 hedge funds and large institutions have $220M invested in IGM Biosciences in 2024 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 21 increasing their positions, 23 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

136% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 11

118% more call options, than puts

Call options by funds: $107K | Put options by funds: $49K

21% more funds holding

Funds holding: 72 → 87 (+15)

20% more capital invested

Capital invested by funds: $183M → $220M (+$37.4M)

1.66% more ownership

Funds ownership: 66.9% → 68.57% (+1.7%)

9% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 23

Holders
87
Holders Change
+15
Holders Change %
+20.83%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
21
Reduced
23
Closed
11
Calls
$107K
Puts
$49K
Net Calls
+$58K
Net Calls Change
-$132K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$7.28M
2
Millennium Management
Millennium Management
New York
+$5.19M
3
BBA
Baker Bros. Advisors
New York
+$4.6M
4
Goldman Sachs
Goldman Sachs
New York
+$2.76M
5
RG
Redmile Group
California
+$1.17M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.42M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.32M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.3M
4
EAM
Exome Asset Management
New York
-$1.13M
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$1.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$39.5M +$4.6M +397,311 +11%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$37.5M +$7.28M +628,001 +19%
AG
3
Artal Group
Luxembourg
$29.7M -$232K -20,000 -0.6%
RG
4
Redmile Group
California
$29.6M +$1.17M +100,936 +3%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$12.7M -$4.42M -381,165 -22%
Goldman Sachs
6
Goldman Sachs
New York
$12.3M +$2.76M +238,110 +23%
RCM
7
RA Capital Management
Massachusetts
$9.05M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$8.24M -$504K -43,491 -5%
BlackRock
9
BlackRock
New York
$7.31M -$52.2K -4,507 -0.6%
Millennium Management
10
Millennium Management
New York
$6.71M +$5.19M +447,865 +181%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$3.24M +$108K +9,349 +3%
State Street
12
State Street
Massachusetts
$3.08M +$137K +11,801 +4%
RPAM
13
Rhenman & Partners Asset Management
Sweden
$1.88M -$57.9K -5,000 -3%
TD Asset Management
14
TD Asset Management
Ontario, Canada
$1.54M +$877K +75,670 +91%
SB
15
Samsara BioCapital
California
$1.49M – – –
Northern Trust
16
Northern Trust
Illinois
$1.32M +$5.1K +440 +0.3%
Charles Schwab
17
Charles Schwab
California
$1.17M +$3.49K +301 +0.2%
Morgan Stanley
18
Morgan Stanley
New York
$976K -$1.03M -88,987 -47%
D.E. Shaw & Co
19
D.E. Shaw & Co
New York
$899K +$532K +45,918 +97%
Jacobs Levy Equity Management
20
Jacobs Levy Equity Management
New Jersey
$758K +$911K +78,580 New
WP
21
Woodline Partners
California
$724K – – –
Marshall Wace
22
Marshall Wace
United Kingdom
$683K +$820K +70,776 New
Manulife (Manufacturers Life Insurance)
23
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$680K +$250K +21,559 +44%
BC
24
Bruce & Co
Illinois
$627K – – –
PI
25
Pennant Investors
New Jersey
$626K – – –
1
2 3 4

IGMS Hedge Fund Activity: Q1 2024 in Review

87 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q1 2024, worth a combined $220M — up 20% from $183M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new IGMS positions and 11 closed out — a net gain of 15 holders — while 21 added to existing stakes and 23 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $7.28M. The largest seller was Fidelity Investments, cutting an estimated $4.42M.

  • 87 institutional investors held IGM Biosciences (IGMS) as of Q1 2024, up from 72 in Q4 2023.
  • Funds reported $220M of IGM Biosciences stock for Q1 2024, up 20% quarter-over-quarter.
  • 26 funds opened new IGM Biosciences positions in Q1 2024 and 11 closed out, a net change of +15 holders.
  • The largest IGM Biosciences buyer in Q1 2024 was T. Rowe Price Associates, an estimated $7.28M added.
  • The largest IGM Biosciences seller in Q1 2024 was Fidelity Investments, an estimated $4.42M sold.

Based on aggregated 13F filings for Q1 2024.